Placebo? no thanks, it might be bad for me!

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 711-714

  Garattini, Silvio ^a   Bertelé, Vittorio ^a   Banzi, Rita ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Clinical methodology; Comparator; Multiple sclerosis; Placebo; Randomized clinical trials

Indexed keywords

4 AMINOPYRIDINE; BETA INTERFERON; CLADRIBINE; DIRUCOTIDE; FINGOLIMOD; GLATIRAMER; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PLACEBO; ROQUINIMEX; TERIFLUNOMIDE;

DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT RIGHT; PATIENT SAFETY; PRIORITY JOURNAL; RELAPSE; REVIEW;

DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PATIENT SAFETY; PEPTIDES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877107408     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1383-6     Document Type: Review

References (29)

1. World Medical Association (1964-2008). The Declaration of Helsinki. Available at: http://www.wma.net/en/30publications/10policies/b3/. Accessed 3 Aug 2012
2. Carlson RV, Boyd KM, Webb DJ (2004) The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol 57:695-713
3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
4. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE III, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH (1995) A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating- remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1:118-135
7. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662-667
8. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, Spada V, Weiss W, Appel S, Rolak L, Harati Y, Brown S, Arnon R, Jacobsohn I, Teitelbaum D, Sela M (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533-539
9. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
10. La Mantia L, Munari LM, Lovati R (2010) Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev (5):CD004678
11. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G (2001) Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev (4):CD002002.
12. Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366:339-347
13. Tan IL, Lycklama à Nijeholt GJ, Polman CH, Ader HJ, Barkhof F (2000) Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 6:99-104
14. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, the Mitoxantrone in Multiple Sclerosis Study Group (M1MS) (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025
15. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, for the CLARITY Study Group (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416-426
16. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Alfred W, Sandrock AW, for the AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
17. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR, on behalf of the MSF204 Investigators (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494-502
18. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732-738
19. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, for the FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401
20. Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung H-P, Krantz M, Ferenczi L, Verco T, on behalf of the MAESTRO-01 Investigators (2011) A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 77:1551-1560
21. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS, for the TEMSO Trial Group (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293-1303
22. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, for the ALLEGRO Study Group (2012) Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. N Engl J Med 366:1000-1009
23. Food and Drug Administration (2009) Interferon beta-1a product approval information - licensing action. Available at: www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080737.htm. Accessed 3 Aug 2012
24. Food and Drug Administration (2009) Interferon beta-1b product approval information - licensing action. Available at: www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080486.htm. Accessed 3 Aug 2012
25. European Medicines Agency. European Public Assessment Report, scientific discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Scientific-Discussion/human/000102/WC500029420.pdf. Accessed 3 Aug 2012
26. European Medicines Agency. European Public Assessment Report, scientific discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Scientific-Discussion/human/000081/WC500053087.pdf. Accessed 3 Aug 2012
27. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297
28. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256-63
29. Temple RT, Ellenberg SS (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133:455-463